About Addex Therapeutics Ltd
Addex Therapeutics Ltd is a biopharmaceutical firm based in Switzerland, dedicated to identifying, developing, and commercializing small-molecule pharmaceutical products designed to address central nervous system (CNS) disorders. The company's primary research endeavor involves discovering oral small-molecule allosteric modulators of G-protein coupled receptors. Its leading development programs feature Dipraglurant, an investigational therapy for levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, aimed at epilepsy and other unspecified CNS conditions; and a GABAB PAM candidate for the treatment of addiction. Addex Therapeutics maintains licensing and collaborative agreements with partners including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Established in 2002, the company, headquartered in Geneva, Switzerland, was formerly known as Addex Pharmaceuticals Ltd before adopting its current name in March 2012.
